Navigation Links
Chimerix to Present at Cowen and Company's 32nd Annual Health Care Conference
Date:3/5/2012

vir-diphosphate and has broad spectrum activity against dsDNA viruses in vitro. CMX001 has completed Phase 2 clinical development for the prophylaxis of CMV and is in Phase 2 development for the preemption and treatment of adenovirus infection in hematopoietic stem cell transplant recipients. Antiviral activity results from completed and ongoing studies, coupled with the lack of myelotoxicity and nephrotoxicity seen in currently available therapies, indicate that CMX001 has the potential to improve outcomes for immunosuppressed patients. To date, more than 700 patients have been dosed with CMX001 in placebo-controlled clinical trials and open-label treatment protocols.

In addition to the company's development of its lead candidate, CMX001 is also being developed as a medical countermeasure in the event of a smallpox release, with the potential to provide an important therapeutic option for the 80 million people in the US currently estimated to be immunocompromised, or a household contact of a contraindicated individual, and thus not candidates to receive a smallpox vaccine (see http://www.bt.cdc.gov/agent/smallpox/vaccination/contraindications-clinic.asp). Chimerix has received federal funding for the development of CMX001 as a medical countermeasure against smallpox from the National Institute of Allergy and Infectious Diseases under Grant No. U01-A1057233 and from the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, Office of the Secretary, Department of Health and Human Services, under Contract No. HHSO100201100013C.

Chimerix's second clinical-stage antiviral compound, CMX157, is a Lipid-Antiviral-Conjugate that delivers high intracellular levels of the active antiviral agent tenofovir-diphosphate. CMX157 is in development as a potent nucleoside analogue against HIV and
'/>"/>

SOURCE Chimerix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Chimerix Initiates a Multi-dose Clinical Trial of the Companys Lead Compound, CMX001, for the Treatment for Smallpox Infection
2. Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
3. Chimerix to Present at Two Upcoming Investor Conferences
4. Chimerix CEO George Painter, Ph.D., to Speak on Improving Biodefense Product Discovery and Development Strategies at Institute of Medicine Workshop
5. Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus
6. Chimerix Appoints Thomas Pitler, Ph.D., Vice President, Business Development
7. Chimerix to Present at 9th Annual BIO Investor Forum
8. Chimerix Reaffirms Its Commitment to CMX001 as a Medical Countermeasure for Smallpox and Broad-Spectrum Antiviral Agent
9. Chimerix to Present at the Lazard Capital Markets 7th Annual Healthcare Conference
10. Chimerixs Antiviral CMX157 Demonstrates Positive Phase 1 Clinical Results With Favorable Pharmacokinetics, Safety and Tolerability
11. Chimerix Commences CMX001 Open-Label Clinical Study for the Treatment of Patients With Life-Threatening or Serious dsDNA Viral Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NEW YORK , Jan. 15, ... a new market research report is ... Global Markets and Technologies ... Focus on Routes of Administration ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... 2014  A novel wearable injector slightly larger than ... painless for patients to self-inject prescription drugs in the ... disorders, including cancer, blood diseases, autoimmune deficiencies, and genetic ... is expected to grow to $220B by 2018, according ... new type of injector that does not exist today ...
(Date:1/14/2014)... 2014  Luminex Corporation (Nasdaq: LMNX ) ... the fourth quarter of 2013 on Monday, February 3, ... for release after the close of trading. ... hold a conference call to discuss the operating highlights ... months ended December 31, 2013 on February 3, 2014, ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
... PRXL ), a leading global biopharmaceutical services ... one of two strategic partners by UCB, a global ... PAREXEL will work with UCB to drive innovation ... and cost effectiveness. The agreement is effective ...
... Reportlinker.com announces that a new market research ... The Outlook for Pharmaceuticals ... http://www.reportlinker.com/p0203103/The-Outlook-for-Pharmaceuticals-in-Central--Eastern-Europe.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication ... Europe is estimated at US$63.6 billion at ...
Cached Medicine Technology:UCB and PAREXEL Sign Strategic Partnership Agreement 2UCB and PAREXEL Sign Strategic Partnership Agreement 3UCB and PAREXEL Sign Strategic Partnership Agreement 4The Outlook for Pharmaceuticals in Central & Eastern Europe 2The Outlook for Pharmaceuticals in Central & Eastern Europe 3The Outlook for Pharmaceuticals in Central & Eastern Europe 4
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... for doctors. Could they work for patients, too? Could ... preventive health services more? In some cases, yes, according ... in Australia, and colleagues. Their work, looking at why ... to change risky health behaviors, indicates that incentives are ...
... Can dementias and mild cognitive impairment be influenced in ... the subject of a study reported by Thorleif Etgen ... rzteblatt International (Dtsch Arztebl Int 2011; 108[44]: 743-50). ... mild cognitive impairments and even dementia, which means that ...
... a woman or a parent and a baby, we can still ... related. How do we know that people are part of a ... of Vision increases our understanding of the brain,s ability to ... to see the family resemblance between faces that have some underlying ...
... with coronary artery disease were almost three times as ... treatment to arterial plaque than their White European counterparts, ... the International Journal of Clinical Practice . They ... and require urgent treatment. Researchers carried out a ...
... with dexpramipexole a novel drug believed to prevent ... most of a cell,s energy appears to slow ... (ALS). Promising results of a phase 2 trial ... Medicine. Some preliminary results of the study were ...
... , SUNDAY, Nov. 20 (HealthDay News) -- A good night,s ... a new study. The findings suggest that age-related brain ... the memory problems that can occur in older adults, the ... older adults who learned how to navigate through a series ...
Cached Medicine News:Health News:It pays to be healthier 2Health News:New research sheds light on how we see family resemblance in faces 2Health News:South Asian patients require 3 times as much repeat angioplasty as white Europeans 2Health News:South Asian patients require 3 times as much repeat angioplasty as white Europeans 3Health News:Novel ALS drug slows symptom progression, reduces mortality in phase 2 trial 2Health News:Novel ALS drug slows symptom progression, reduces mortality in phase 2 trial 3
... System supports approaches to Admitting/Discharge/Transfer ... record keeping functions using a ... facilities and cut across institutional ... community clinics, physician, agency, nursing ...
... Dairylands Clinical Information Management ... suite of integrated applications ... departments and automate administrative ... The applications allow organizations ...
... include a Patient Face Sheet, ... many as six custom tabs, ... information is important for you ... Import Manager utility lets you ...
... WEBeDoctor® Physician-office® is an ... physicians, (Solo practice, group ... to complete their normal ... It is a front ...
Medicine Products: